The complete study cohort includes 1,023 patients from 22 sites in Europe.
The trial is evaluating VIR-5500 with an androgen receptor pathway inhibitor in early-line mCRPC and mHSPC.
The FDA has scheduled a decision date for 10 October 2026 under the Prescription Drug User Fee Act.
Aiva’s AI assistant enables nurses to use natural voice commands for documentation and work order submissions.
